Developing Covalent Protein Drugs via Proximity-Enabled Reactive TherapeuticsLi et al. present a general synthetic biotechnology platform to create covalent protein biologics from various protein-protein interactions by incorporating an unnatural amino acid with latent bioreactivity into one of the proteins, which can then target the other in vitro, on cell surfaces, and in mice. As a proof of concept, the authors create a synthetic form of PD-1 that enhances the activation of T cells and CAR-T cells more than wildtype PD-1 and can inhibit tumor growth more potently in immune-humanized mice by binding covalently to PD-L1.Li et al. present a general synthetic biotechnology platform to create covalent protein biologics from various protein-protein interactions by incorporating an unnatural amino acid with latent bioreactivity into one of the proteins, which can then target the other in vitro, on cell surfaces, and in mice. As a proof of concept, the authors create a synthetic form of PD-1 that enhances the activation of T cells and CAR-T cells more than wildtype PD-1 and can inhibit tumor growth more potently in immune-humanized mice by binding covalently to PD-L1.Qingke Li, Qu Chen, Paul C. Klauser, Mengyuan Li, Feng Zheng, Nanxi Wang, Xiaoying Li, Qianbing Zhang, Xuemei Fu, Qian Wang, Yang Xu, Lei Wanghttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2930623-1%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignJune 24, 2020

Powered by WPeMatico